In line with this finding, it was recently shown that the serum neurofilament light chain concentration, a biomarker for axonal damage associated with disease severity in GBS, did not differ over time between the SID and the placebo group, suggesting that an additional IVIg course did not prevent axonal damage.18 Here, NEFL is linked to Guillain-Barre syndrome.